{
    "clinical_study": {
        "@rank": "95959", 
        "acronym": "FAST", 
        "arm_group": [
            {
                "arm_group_label": "F17464", 
                "arm_group_type": "Experimental", 
                "description": "Oral administration - During 6 weeks - 4 capsules daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Oral administration - During 6 weeks - 4 capsules daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the potential efficacy of oral F17464 in comparison\n      to placebo over 6 weeks in patients with acute exacerbation of schizophrenia. Study design:\n      double-blind, randomized, placebo-controlled, parallel-groups, fixed-dose design,\n      multicentre study."
        }, 
        "brief_title": "F17464 in Acute Schizophrenia Trial", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Demographic and other characteristics\n\n          -  Male or female, 18-64 years of age inclusive\n\n          -  primary diagnosis of schizophrenia undergoing an acute exacerbation with prominent\n             \"active phase\" symptoms, as described by the Diagnostic and Statistical Manual of\n             Mental Disorders, 4th edition - Text Revision (DSM IV-TR) using the MINI 6.0\n             (Mini-International Neuropsychiatric Interview) for schizophrenia and psychotic\n             disorders related to DSM IV-TR\n\n          -  For a minimum of 1 year and maximum 5 years, well-documented diagnosis with the first\n             hospitalization for acute exacerbation of schizophrenia\n\n          -  Since the diagnosis of schizophrenia, the average number of hospitalisations should\n             be no higher than 2 per year (the minimum duration of hospitalization should be more\n             than 4 days)\n\n          -  During the year before Visit 1, maximum 3 acute psychotic episodes that required\n             hospitalization or change of antipsychotic medication or other therapeutic\n             intervention\n\n          -  Adequate clinical response to well-conducted treatment courses during previous acute\n             episodes. A well conducted treatment course is defined as an antipsychotic treatment\n             with the usual doses for at least 4 weeks\n\n        Current acute episode\n\n          -  Structured Clinical Interview for the Positive And Negative Syndrome Scale\n             (SCI-PANSS) with a PANSS total score \u2265 70 to < 120 (at Visit 1 and 2)\n\n          -  Rating of at least 4 (moderate) on at least 2 of the following 4 PANSS positive\n             symptoms: delusions, hallucinatory behaviour, conceptual disorganization,\n             suspiciousness/persecution\n\n          -  Clinical Global Impression of Severity (CGI-S) score \u2265 4 (moderate or severe)\n\n          -  Antipsychotic initiated for this acute episode and/or ongoing chronic antipsychotic\n             treatment, with a maximum of 2 antipsychotics in total needed to be changed (due to\n             inefficacy or safety reasons)\n\n          -  Hospitalization and/ or treatment for the current psychotic episode for less than 2\n             weeks prior to Visit 1\n\n          -  No significant improvement of PANSS total score between enrolment (Visit 1) and\n             inclusion (Visit 2) corresponding to a score improvement < 20% on positive symptoms\n             subscale\n\n        Exclusion Criteria:\n\n        Related to the pathology\n\n          -  Patients in their first acute episode of psychosis\n\n          -  Current schizophrenic episode with predominant negative symptoms\n\n          -  Patient \" known to be refractory \" defined as lack of significant improvement (no\n             significant relief of symptoms, and no period of good function) despite adequate\n             courses with at least 3 different antipsychotics medication cycles of an adequate\n             duration (at least 4 weeks) and at adequate dosage during the previous 5 years;\n\n          -  Schizoaffective disorder, schizophreniform disorder and other psychotic disorders;\n\n          -  Bipolar I and II disorder\n\n          -  Pervasive developmental disorder, mental retardation, delirium, dementia, memory\n             impairment and other cognitive disorders that would compromise a reliable assessment\n             according to the investigator's opinion\n\n          -  Known or suspected borderline or antisocial personality disorder or other DSM IV axis\n             II disorder of sufficient severity to interfere with participation in this study\n\n          -  History of tardive dyskinesia or chronic extra-pyramidal symptoms (EPS), serotonin\n             syndrome or neuroleptic malignant syndrome\n\n          -  Major depressive disorder which requires a pharmacological treatment\n\n          -  At imminent risk of injuring him/herself or others or causing significant damage to\n             property, as judged by the investigator\n\n          -  Suicidal risk based on the Columbia-Suicide Severity Rating Scale (C-SSRS)\n\n               -  Any suicidal behavior in the past year\n\n               -  Suicidal ideation of type 4 or 5 in the past month\n\n        Related to treatments\n\n          -  Structured psychotherapy (e.g. cognitive behavioural therapy) started within 6 weeks\n             before visit 1\n\n          -  Electroconvulsive therapy within 3 months before Visit 1\n\n          -  Previous lack of response to electroconvulsive therapy\n\n          -  Treatment ongoing with a depot neuroleptic (even if less than 1 cycle in duration\n             before Visit 1)\n\n          -  Patient having previous treatment course with clozapine within the 4 months prior to\n             Visit 1\n\n          -  Requirement of concomitant treatment with any of the prohibited medications\n\n          -  History of intolerance or hypersensitivity to other drugs of the same chemical class\n             as F17464 or to rescue medications or any history of severe drug allergy or\n             hypersensitivity"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "142", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02151656", 
            "org_study_id": "F17464 GE 2 01", 
            "secondary_id": "2013-005451-32"
        }, 
        "intervention": [
            {
                "arm_group_label": "F17464", 
                "intervention_name": "F17464", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antipsychotic Agents"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Schizophrenia", 
            "Mental disorders", 
            "Antipsychotic Drugs"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Clermont Ferrand", 
                        "country": "France"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "N\u00eemes", 
                        "country": "France"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sotteville les Rouen", 
                        "country": "France"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of F17464 in Acute Exacerbation of Schizophrenia", 
        "overall_contact": {
            "email": "contact_essais_cliniques@pierre-fabre.com", 
            "last_name": "Pierre Fabre M\u00e9dicament"
        }, 
        "overall_official": {
            "affiliation": "Pierre Fabre Medicament", 
            "last_name": "Fran\u00e7oise TONNER, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes", 
                "Hungary: Institutional Ethics Committee", 
                "Hungary: National Institute of Pharmacy", 
                "Romania: Ethics Committee", 
                "Romania: National Agency for Medicines and Medical Devices", 
                "Lithuania: Bioethics Committee", 
                "Lithuania: State Medicine Control Agency - Ministry of Health", 
                "Latvia: State Agency of Medicines", 
                "Latvia: Institutional Review Board", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Russia: Ethics Committee"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline to Day 43 of the PANSS total score", 
            "measure": "Change of the Positive and Negative Syndrome Scale (PANSS) total score", 
            "safety_issue": "No", 
            "time_frame": "Day 43"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02151656"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pierre Fabre Medicament", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pierre Fabre Medicament", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}